Biotechnology company, Leukocare, and pharma company, Boehringer Ingelheim, have entered into a licence agreement in the field of veterinary diagnostics.
Veterinary
Under the terms of the agreement, the animal health business unit of Boehringer Ingelheim will have access to Leukocare’s SPS technologies in order to use biological reagents in a new veterinary diagnostics product and to stabilise them. The SPS technologies improve stability and quality of biologics, like antibodies and vaccines, in dry and liquid formulation including high-concentration formulations. Additionally, they protect proteins in biologically functionalised combination devices.
“Thanks to LEUKOCARE's expertise and its SPS technologies, we have been able to develop a new diagnostic concept in animal health,” commented Rolf-Dieter Günther, head of diagnostics at Boehringer Ingelheim. “The diagnostics platform will enable veterinarians to get a quick, easy and safe test to be performed directly at the stable or at the pet owner's home.”
“After having already worked with Boehringer Ingelheim for a longer period of time and being closely involved in their development activities, we are delighted to support our partner with our SPS technologies in this exciting application,” said Michael Scholl, CEO of Leukocare. “This once again proves the high quality of our SPS formulation technology platform, and, on the other hand, our outstanding development skills.”